CINCINNATI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® On-Body Delivery System, today announced ...
CINCINNATI, March 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® wearable drug delivery platform, today ...
Collaboration underscores both companies’ commitment to advancing patient-centric solutions and expanding access to therapies through novel drug delivery technologies Under the terms of the agreement, ...
CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® on-body drug delivery system, announced ...
CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse ® On-Body Delivery System (OBDS), announced ...
CINCINNATI, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® wearable drug delivery platform, and ...
CINCINNATI, Feb. 14, 2024 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and manufacturing the enFuse ® platform of wearable technology, today announced it plans ...
CINCINNATI, Feb. 7, 2024 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and manufacturing the enFuse ® platform of wearable drug delivery systems, today ...
Under the terms of the agreement, Incyte will obtain a worldwide, exclusive license to use the enFuse technology with its mutCALR-targeted therapy (INCA033989) in essential thrombocythemia (ET) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results